Description:
This is a single arm, open-label, multi-center, Phase 1 study to determine safety and
tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting
NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high
risk relapsed/refractory MDS
Title
- Brief Title: NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS
- Official Title: A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Clinical Trial IDs
- ORG STUDY ID:
NKX101-101
- NCT ID:
NCT04623944
Conditions
- Relapsed/Refractory AML
- AML, Adult
- MDS
- Refractory Myelodysplastic Syndromes
Interventions
Drug | Synonyms | Arms |
---|
NKX101 - CAR NK cell therapy | Cyclophosphamide, Fludarabine | NKX101 - CAR NK cell therapy |
Purpose
This is a single arm, open-label, multi-center, Phase 1 study to determine safety and
tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting
NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high
risk relapsed/refractory MDS
Detailed Description
This is a dose-finding study of NKX101 and will be conducted in 2 parts:
Part 1: dose finding with two dosing regimens, utilizing modified "3+3" enrollment schema.
Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics,
pharmacodynamics and anti-tumor response in expansion cohorts of patients with either AML or
MDS.
Trial Arms
Name | Type | Description | Interventions |
---|
NKX101 - CAR NK cell therapy | Experimental | All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 or 2 weekly doses of NKX101. Regimen A will dose on Day 0, 7, and 14 of a 28-day cycle. Regimen B will dose on Day 0 and 7 of a 28-day cycle.
Part 1: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used
Part 2: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used | - NKX101 - CAR NK cell therapy
|
Eligibility Criteria
Inclusion Criteria:
- General:
- ECOG performance status ≤2
- Haplo-matched related subjects require a suitable haplo-matched related donor,
who is able and willing to undergo leukapheresis
- Disease related:
- For AML subjects:
- Previously treated relapsed/refractory AML, including subjects with MRD+
disease
- White blood cell count of ≤25 × 10^9/L
- For MDS subjects:
- Intermediate-, high-, or very high-risk MDS
- Previously treated relapsed/refractory MDS
- Adequate Organ Function
- Platelet count ≥30,000/uL (platelet transfusions acceptable)
- Other:
- Signed informed consent
- Agree to use an effective barrier method of birth control
Exclusion Criteria:
- Disease related:
- Acute promyelocytic leukemia with t(15;17) (q22;q12); or abnormal promyelocytic
leukemia/retinoic acid receptor alpha (APML-RARA)
- Evidence of leukemic meningitis or known active central nervous system disease
- Use of any anti-AML/MDS chemotherapeutic or targeted small molecule drug within
protocol specified window prior to the first dose of NKX101
- Presence of residual non-hematologic toxicity from prior therapies that has not
resolved to ≤ Grade 1
- Any hematopoietic cell transplantation within 16 weeks
- Other comorbid conditions and concomitant medications prohibited as per study protocol
- Other:
- Pregnant or lactating female
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] |
Time Frame: | 30 days after last dose of NKX101 |
Safety Issue: | |
Description: | Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease. |
Secondary Outcome Measures
Measure: | Assessment of NKX101 half-life |
Time Frame: | 28 days from first dose of NKX101 |
Safety Issue: | |
Description: | Time required for 50% reduction from maximum amount of circulating NKX101 |
Measure: | NKX101 duration of persistence |
Time Frame: | Followed up to 2 years after last dose of NKX101 |
Safety Issue: | |
Description: | Testing NKX101 in peripheral blood every 3 months after dosing to determine persistence |
Measure: | Evaluation of host immune response against NKX101 |
Time Frame: | Followed up to 2 years after last dose of NKX101 |
Safety Issue: | |
Description: | Serum samples will be measured for antibodies against NKX101 |
Measure: | Objective response rate to NKX101 |
Time Frame: | Primary assessment: 28 days after first dose of NKX101 followed up to 2 years after last dose of NKX101 |
Safety Issue: | |
Description: | Percentage of subjects with complete and partial response. AML subjects will be assessed for anti-tumor activity of NKX101 based on the updated ELN criteria (Döhner 2017). Subjects with MDS will be assessed for anti-tumor activity of NKX101 based on the IWG criteria with MDS (Cheson 2006). |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Nkarta Inc. |
Trial Keywords
- NKG2D
- CAR
- Allogeneic
- Natural killer
- ACR
- NKX101
- IL15
- Interleukin 15
- NK cell
- Cell Therapy
- Immunotherapy
- Adoptive cell therapy
- r/r AML
- Off-the-shelf
Last Updated
May 17, 2021